Talaporfin

Talaporfin

Talaporfin (also known as LS11) is a photosensitizer used in photodynamic therapy (PDT). It is a second-generation photosensitizer, developed to overcome some of the limitations of earlier, first-generation photosensitizers. Talaporfin is activated by light of a specific wavelength, leading to the production of reactive oxygen species that can kill cells.

History

Talaporfin was developed by Light Sciences Corporation, a company specializing in the development of light-activated drugs. The drug was first approved for use in Japan in 2004, for the treatment of early-stage lung cancer.

Mechanism of Action

Talaporfin is administered intravenously and accumulates in tumor cells. When exposed to light of a specific wavelength, talaporfin is activated and produces reactive oxygen species. These reactive oxygen species can damage cellular components, leading to cell death. This mechanism of action is similar to that of other photosensitizers used in photodynamic therapy.

Clinical Use

Talaporfin is used in photodynamic therapy for the treatment of various types of cancer, including lung cancer and esophageal cancer. The drug is also being investigated for use in the treatment of other conditions, such as age-related macular degeneration.

Side Effects

As with other photosensitizers, the use of talaporfin can lead to photosensitivity reactions. These reactions can occur if the patient is exposed to light after receiving the drug. Other potential side effects include nausea, vomiting, and pain at the injection site.

See Also

• Photodynamic therapy
• Photosensitizer
• Reactive oxygen species

This article is a stub related to pharmacology. You can help WikiMD by expanding it!